WA-KYMETA
23.3.2022 14:02:14 CET | Business Wire | Press release
Kymeta (www.kymetacorp.com ), the communications company making mobile global, and IP Access International (www.ipinternational.net ), a leading mobile and fixed satellite solutions provider, announced today the signing of a partnership agreement to co-develop and distribute optimized solutions using Kymeta terminals, broadband and LTE services to first responders across North America.
Today, IP Access operates the nation’s largest public safety satellite network, which includes over 1,000 agency customers encompassing 1,700 unique endpoints. This agreement to deliver optimized solutions will combine Kymeta’s resilient and cost-effective electronically-steered flat panel technology with IP Access’ experience building public safety networks for mobility and remote connectivity where it has not previously existed. It will utilize coverage and bandwidth on a jointly developed, multi layered broadband network optimized specifically for public safety customers. The Kymeta enabled solution allows communication and interoperability among devices, further extending the reach of the IP Access RedPHONE service even if there is an internet outage due to malware or denial-of-service attacks.
“Kymeta is dedicated to bringing access to always-on, reliable, and mission-critical communications while on the move to the public safety and first responder market,” said Bill Marks, EVP and Chief Development Officer of Kymeta. “Our u8 products have been deployed around the world and provide a real-world solution for the defense, government, public safety, and commercial industries by enabling connectivity that is ubiquitous and more robust than ever before. We are pleased to partner with a well-established leader like IP Access who has earned the continued trust and loyalty of first responders for over two decades through the delivery of consistent, reliable products and services.”
“IP Access looks forward to a strong partner relationship with Kymeta in our joint efforts to provide resilient communications to response teams who protect and save lives,” said Bryan Hill, CEO of IP Access International. “Our customers are indifferent to what network they are on so long as it is reliable. Our goal at IP Access is to provide them with the connectivity they need on every possible network. That means 4G, 5G, GEO, MEO and LEO. Customers have capital constraints, and it is our responsibility to deliver solutions that are future proof and that is why we are partnering with Kymeta.”
The Kymeta u8 product family for mobile broadband communications are low-maintenance and low-profile for resilient communications-on-the-move (COTM) and communications-on-the-pause (COTP). The u8 product family also offers a pathway to low Earth orbit (LEO) networks as they come online over the next several years. The new partnership will allow IP Access to provide solutions that perform on today’s satellites and are enabled to work on future LEO satellite networks.
The partnership illustrates the commitment from both companies to enable critical mobile connectivity solutions for public safety and for disaster response that are more robust than ever before. Kymeta and IP Access have committed to a significant volume of equipment and satellite bandwidth to quickly fulfill the needs of public safety and first responders and grow the product suite and coverage in support of this important market.
About Kymeta
Kymeta is the leader in unlocking the potential of broadband satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for communications-on-the-move and making mobile global. Kymeta satellite connectivity solutions offer unique, complete, and turnkey bundled solutions to the market based on best-in-class technologies and tailored customer-centric services that meet and exceed customer mission requirements. These solutions, in tandem with the company’s flat-panel satellite antenna, the first of its kind, and Kymeta services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for low-power, low-cost, and high-throughput communication systems that have no moving parts. Kymeta makes connecting easy – for any vehicle, vessel, aircraft, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com
About IP Access International
IP Access is a leading provider of mobile and fixed satellite internet solutions with over 20 years experience serving the satellite industry as a domestic and global provider. IP Access provides complete satellite communications solutions inclusive of satellite network offerings, terminal hardware, and installation and support services. Incorporated in 1999, today IP Access operates the nation’s largest satellite network of public safety agencies, which includes over 1000 agency customers encompassing 1,700 unique endpoints. At the heart of the IP Access offering is the SELECT Network, providing multiple satellite options and multiple teleports, ensuring protection against regional disasters and infrastructure disruptions while also allowing for on-demand user selectable satellite service in the event of line-of-sight or look angle obstructions.
For more information, visit ipinternational.net
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005277/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom